Literature DB >> 17410638

Isolated tumour cells in blood and E-cadherin expression in oesophageal squamous cell cancer.

T Setoyama1, S Natsugoe, H Okumura, M Matsumoto, Y Uchikado, T Aikou.   

Abstract

BACKGROUND: Patients with oesophageal squamous cell carcinoma have a high rate of recurrence, even after curative resection. The aim of this study was to examine the correlation between the presence of isolated tumour cells (ITCs) in the blood and recurrence, and between the presence of ITCs and E-cadherin expression in the primary tumour in these patients.
METHODS: Blood samples obtained immediately before and after resection in 125 patients with oesophageal squamous cell carcinoma were examined by real-time reverse transcription-polymerase chain reaction using carcinoembryonic antigen mRNA. Blood samples from 28 healthy volunteers and 42 patients with benign diseases were used as controls.
RESULTS: Seventy-seven patients (61.6 per cent) were ITC positive. ITC positivity correlated significantly with tumour depth, lymph node metastasis, stage, lymphatic invasion and venous invasion. Multivariable analysis revealed that tumour depth and ITC positivity were independent factors for a shortened haematogenous disease-free interval. A significant correlation was found between ITC positivity and reduced E-cadherin expression in the primary tumour (P < 0.001). ITC-positive patients with preserved E-cadherin expression had a longer disease-free interval (P = 0.016), haematogenous disease-free interval (P = 0.020) and overall survival (P = 0.004) than those with reduced E-cadherin expression.
CONCLUSION: Examination of ITCs in the blood is useful for predicting haematogenous recurrence in patients with oesophageal squamous cell carcinoma. Copyright (c) 2007 British Journal of Surgery Society Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17410638     DOI: 10.1002/bjs.5717

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  7 in total

Review 1.  The biological and clinical importance of epithelial-mesenchymal transition in circulating tumor cells.

Authors:  Huiying Liu; Xiaofeng Zhang; Jun Li; Bin Sun; Haihua Qian; Zhengfeng Yin
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-26       Impact factor: 4.553

2.  Significant prognostic value of circulating tumor cells in esophageal cancer patients: A meta-analysis.

Authors:  Shuyu Wang; Hongyang Du; Guixia Li
Journal:  Oncotarget       Date:  2017-02-28

3.  Tumor microenvironment promotes prostate cancer cell dissemination via the Akt/mTOR pathway.

Authors:  Junlin Shi; Lihui Wang; Chunlin Zou; Yudui Xia; Siyuan Qin; Evan Keller; Atsushi Mizokami; Jian Zhang; Yi Lu
Journal:  Oncotarget       Date:  2018-01-09

Review 4.  Clinicopathological and prognostic significance of circulating tumor cells in patients with esophageal cancer: a meta-analysis.

Authors:  Jinxuan Hou; Kun Zou; Chaogang Yang; Xiaohua Leng; Yu Xu
Journal:  Onco Targets Ther       Date:  2018-11-12       Impact factor: 4.147

5.  Circulating tumor cells detected in follow-up predict survival outcomes in tri-modality management of advanced non-metastatic esophageal cancer: a secondary analysis of the QUINTETT randomized trial.

Authors:  Edward Yu; Alison L Allan; Michael Sanatani; Debra Lewis; Andrew Warner; A Rashid Dar; Brian P Yaremko; Lori E Lowes; David A Palma; Jacques Raphael; Mark D Vincent; George B Rodrigues; Dalilah Fortin; Richard I Inculet; Eric Frechette; Joel Bierer; Jeffery Law; Jawaid Younus; Richard A Malthaner
Journal:  BMC Cancer       Date:  2022-07-08       Impact factor: 4.638

6.  Seed, soil, and beyond: The basic biology of brain metastasis.

Authors:  Rohan Ramakrishna; Robert Rostomily
Journal:  Surg Neurol Int       Date:  2013-05-02

7.  Prognostic significance of circulating tumor cells in esophageal carcinoma: a meta-analysis.

Authors:  Guang-Lei Qiao; Wei-Xiang Qi; Wei-Hua Jiang; Ying Chen; Li-Jun Ma
Journal:  Onco Targets Ther       Date:  2016-03-31       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.